Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM

Table 1

Primary chemotherapeutic agents in HR consolidation therapy.

Scheme	Agent	Daily dose	Duration (day)	Route	d1	d2	d3	d4	d5	d6
HR-1	DXM	20 mg/m^2	5	OR/IV	√	√	√	√	√
	VCR	1.5 mg/m^2	2	IV	√					√
	HD-MTX	5 000 mg/m^2	1	IV	√
	CTX	400 mg/m^2	2.5	IV		√	√	√
	HD-Ara-C	4 000 mg/m^2	1	IV					√
	PEG-ASP	2 500 U/m^2	1	IM						√
	TIT	Based on age	1	IT	√
HR-2	DXM	20 mg/m^2	5	OR/IV	√	√	√	√	√
	VDS	3 mg/m^2	2	IV	√					√
	HD-MTX	5000 mg/m^2	1	IV	√
	IFO	1 600 mg/m^2	2.5	IV		√	√	√
	DNR	30 mg/m^2	1	IV					√
	PEG-ASP	2500 U/m^2	1	IM						√
	TIT	Based on age	1	IT	√
HR-3	DXM	20 mg/m^2	5	OR/IV	√	√	√	√	√
	HD-Ara-C	4000 mg/m^2	2	IV	√	√
	VP-16	200 mg/m^2	2.5	IV			√	√	√
	PEG-ASP	2500 U/m^2	1	IM						√
	TIT	Based on age	1	IT					√

Note: HR, high risk; DXM, dexamethasone; VCR, vincristine; HD-MTX, high-dose methotrexate; CTX, cyclophosphamide; HD-Ara-C, high-dose cytarabine; PEG-ASP, pegylated asparaginase; TIT, triple intrathecal therapy; VDS, vindesine; IFO, ifosfamide; DNR, daunorubicin; VP-16, etoposide; OR, orally; IV, intravenously; IM, intramuscularly; IT, intrathecally.